STAT+: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy
STAT
OCTOBER 5, 2023
Orchard shareholders stand to earn another $90 million if Orchard’s gene therapy, Libmeldy, wins U.S. Kyowa Kirin is paying $16 per share — a nearly 100% premium on Orchard’s Wednesday closing price — in cash, amounting to roughly $390 million. The transaction is expected to close early next year.
105 
Let's personalize your content